Neuronetics' (STIM) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings reaffirmed a "sell (e+)" rating for Neuronetics (NASDAQ: STIM) in a recent research report, indicating a bearish outlook on the stock.
• Canaccord Genuity Group lowered their target price for Neuronetics from $8.00 to $7.00 while maintaining a "buy" rating, suggesting mixed sentiments from analysts.
• Neuronetics reported a quarterly earnings loss of ($0.15) per share, missing estimates, despite recording revenue of $38.11 million, which surpassed analyst expectations.

Neuronetics (NASDAQ:STIM - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, Canaccord Genuity Group reduced their target price on Neuronetics from $8.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $7.00.

Neuronetics Stock Up 2.1%

NASDAQ:STIM opened at $2.97 on Wednesday. The firm has a market capitalization of $196.38 million, a price-to-earnings ratio of -2.63 and a beta of 1.17. Neuronetics has a twelve month low of $0.52 and a twelve month high of $5.92. The stock's 50 day moving average price is $3.33 and its two-hundred day moving average price is $3.72. The company has a quick ratio of 1.84, a current ratio of 2.02 and a debt-to-equity ratio of 1.76.

Neuronetics (NASDAQ:STIM - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.07). Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%.The company had revenue of $38.11 million for the quarter, compared to analyst estimates of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Neuronetics will post -1.13 earnings per share for the current fiscal year.

Institutional Trading of Neuronetics

Institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new stake in Neuronetics in the 1st quarter valued at $1,055,000. Assenagon Asset Management S.A. bought a new stake in Neuronetics in the 1st quarter valued at $359,000. Josh Arnold Investment Consultant LLC bought a new stake in shares of Neuronetics during the 1st quarter valued at $736,000. Kestra Private Wealth Services LLC bought a new stake in shares of Neuronetics during the 1st quarter valued at $254,000. Finally, Informed Momentum Co LLC bought a new stake in shares of Neuronetics during the 1st quarter valued at $385,000. 53.59% of the stock is currently owned by institutional investors.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.